A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis
Top Cited Papers
Open Access
- 24 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (2), 230-236
- https://doi.org/10.1093/cid/cit234
Abstract
Background. The long-term effect of sustained virologic response (SVR) to antiviral therapy on the risk of developing hepatocellular carcinoma (HCC), liver complications, liver-related death, and overall death in hepatitis C virus (HCV)–infected patients with liver cirrhosis is not fully known. Methods. These risks were evaluated during long-term follow-up in 351 patients with HCV-related cirrhosis. One hundred ten patients with SVR, 193 with non-SVR, and 48 who were untreated were included in a multicenter cohort that was initiated in 2001 and prospectively followed up for a mean of 5.3 (SD, 2.8) years. Complementary follow-up data from national registries were used to minimize the loss of patients during follow-up. Results. Six patients with SVR developed HCC at 0.04, 0.64, 2.4, 7.4, 7.4, and 7.6 years, respectively, after achieving SVR. The incidences of HCC, any liver complication, liver-related death, and overall death per 100 person-years were significantly lower in SVR time with 1.0, 0.9, 0.7, and 1.9, compared to 2.3, 3.2, 3.0, and 4.1 in non-SVR and 4.0, 4.9, 4.5, and 5.1 in untreated time. The long-term consequences did not decline significantly after >3 years versus during the first 3 years of follow-up. Conclusions. The risk for HCC, liver decompensation, and death in patients with liver cirrhosis related to HCV was markedly reduced after SVR, but a long-term risk of developing HCC remains for up to 8 years. Cirrhotic patients with HCV who achieve SVR should therefore maintain long-term surveillance for HCC. Future studies aimed to better identify those with remaining long-term risk for HCC are needed.This publication has 22 references indexed in Scilit:
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Telaprevir for Retreatment of HCV InfectionThe New England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting ResponseThe American Journal of Gastroenterology, 2010
- Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver DiseaseGastroenterology, 2009
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced FibrosisAnnals of Internal Medicine, 2007
- Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective studyHepatology, 2007
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001